Overview
The purpose of this study is to investigate whether there are differential expressions of molecules in the kallikrein-kinin system (KKS) pathway in septic cardiomyopathy, and to analyze their regulatory mechanisms and gene expression changes.
Description
This study is designed as a prospective, single-center, prospective case-control study. The research plan mainly aims to collect clinical data and blood samples from patients with septic cardiomyopathy and the control group within the next 3 years (October 2023 to October 2025). Diagnostic criteria are as follows: (1) Diagnosis of sepsis is based on the SEPSIS 3.0 criteria, which is defined as a rapid increase in SOFA score by ≥2 points after infection as a clinical criterion for sepsis-related organ dysfunction. (2) Diagnostic criteria for septic cardiomyopathy include: diagnosis of sepsis and elevation of cardiac markers [cardiac troponin I (cTnI) or BNP]; systolic dysfunction: echocardiography shows LVEF < 50%; diastolic dysfunction: Doppler ultrasound shows an E/A ratio (rapid filling phase/atrial contraction phase) ≤1 at the mitral valve; BNP > 200 pg/mL; left ventricular fractional shortening (FS) > 25%; normal or increased wall thickness, decreased left ventricular filling rate.
Eligibility
Inclusion Criteria:
(1) Age range greater than 18 years. (2) Patients diagnosed with septic cardiomyopathy. (3)
Clear determination of the cause of myocardial injury, such as the source of infection,
bacterial culture results, etc. (4) Patients who are capable of cooperating and completing
the necessary examinations and treatments.
-
Exclusion Criteria:
(1) Presence of other significant underlying cardiovascular diseases, such as coronary
heart disease, heart failure, etc. (2) Presence of other organ dysfunction that poses a
significant threat to life, such as respiratory failure, liver failure, etc. (3) Presence
of severe infections or inflammatory diseases unrelated to myocardial injury, such as
severe acute pancreatitis. (4) History of receiving interventional treatments, such as
immunomodulatory agents, anti-inflammatory drugs, etc. (5) Pregnant or lactating women. (6)
Pediatric patients who are under the age of majority.
-